TransMedics Group, Inc. (TMDX) EPS Basic: 4.37
Is TransMedics Group, Inc.’s EPS basic high or low?
TransMedics Group, Inc.'s EPS basic of 4.37 is 1273% above its 5-year average of 0.32, near the high end of its 5-year range (-1.60–5.60).
31.03% above its 12-month average of 3.33.
TMDX EPS Basic Chart
TMDX Average EPS Basic Chart
TMDX Current vs Average EPS Basic Chart
TMDX EPS Basic Metrics
EPS BASIC
4.37
EPS BASIC AVG TTM
3.33
EPS BASIC AVG 3Y
1.17
EPS BASIC AVG 5Y
0.32
EPS BASIC AVG 10Y
N/A
EPS BASIC AVG 15Y
N/A
EPS BASIC AVG 20Y
N/A
CURRENT VS TTM AVG
+31.03%
CURRENT VS 3Y AVG
+274.30%
CURRENT VS 5Y AVG
+1272.77%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TransMedics Group, Inc. EPS Basic Formula & Definition
EPS Basic is earnings per common share before the effect of potentially dilutive securities. It shows how much profit is attributable to each current common share.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. EPS Basic FAQ
- What is the EPS basic for TransMedics Group, Inc. (TMDX)?
- The EPS basic for TMDX stock is 4.37.
- Is TransMedics Group, Inc.'s EPS basic high or low?
- TransMedics Group, Inc.'s EPS basic of 4.37 is 1273% above its 5-year average of 0.32, near the high end of its 5-year range (-1.60–5.60).
- What is the TTM average EPS basic for TransMedics Group, Inc. (TMDX)?
- The TTM average EPS basic for TMDX stock is 3.33.
- What is the 3Y average EPS basic for TransMedics Group, Inc. (TMDX)?
- The 3Y average EPS basic for TMDX stock is 1.17.
- What is the 5Y average EPS basic for TransMedics Group, Inc. (TMDX)?
- The 5Y average EPS basic for TMDX stock is 0.32.
TransMedics Group, Inc. EPS Basic History
| DATE | EPS BASIC |
|---|---|
| 2025-12-31 | 5.60 |
| 2024-12-31 | 1.07 |
| 2023-12-31 | -0.77 |
| 2022-12-31 | -1.23 |
| 2021-12-31 | -1.60 |
| 2020-12-31 | -1.16 |
| 2019-12-31 | -2.36 |
| 2018-12-31 | -1.23 |
| 2017-12-31 | -1.44 |
| 2016-12-31 | -1.66 |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein